Mitral annular calcification (MAC) is a slowly progressive disease that results in calcification of the fibrous portion of the mitral annulus. 1 It was first identified and recognized as a new entity in 1910 by Dewitzky, where he presented a pathological report of 36 cases and described his finding as a non-inflammatory calcific disease of the mitral annulus fibrosus. 1 The estimated prevalence of MAC is 10%, with a predilection for the posterior annulus. 1 Predisposing factors for MAC include advanced age, female sex, chronic kidney disease, and conditions predisposing to left ventricular (LV) hypertrophy including hypertension, hypertrophic cardiomyopathy, and aortic stenosis (AS). 2 MAC appears to be a multifactorial condition resulting from a varying combination of abnormal calcium and phosphorus metabolism, 3 increased mitral valve haemodynamic stress, 4 and atherosclerotic processes. 5, 6 Patients with MAC have been associated with a higher risk of cardiovascular disease, cardiovascular death, and allcause mortality. 7, 8 MAC has also been found to increase the incidence of mitral valve disease and arrhythmias, as well as influence the outcome of mitral valve surgery. 7 Previously, echocardiography was considered the best method to demonstrate MAC, but cardiac computed tomography (CT) is superior for evaluating the extent and location of MAC and for quantifying MAC objectively in order to assess its severity. 2 In this issue of the journal, Abramowitz et al. evaluated the prevalence of MAC among patients with severe AS and assessed for the first time the clinical implications of MAC following transcatheter aortic valve replacement (TAVR). 9 MAC was a common finding in half of the patients undergoing TAVR, and severe MAC was present in 10% of patients. As shown previously, patients with MAC were older, mainly female, had higher incidence of chronic kidney disease, higher STS (Society of Thoracic Surgeons) scores, higher pressure gradients over the aortic valve, and increased LV outflow tract (LVOT) calcifications. MAC was found to affect important endpoints after TAVR, including mortality and post-procedural pacemaker (PPM) implantation. The STS-PROM risk models and the logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) models were developed to predict risk in conventional surgical procedures such as SAVR (surgical aortic valve replacement). Despite the widespread application of these scores in predicting risk in patients undergoing TAVR, the models were not particularly developed for a patient population undergoing this procedure and thus their application in this background is questionable. 10, 11 This is evident where there is an overestimation of actual mortality compared with the predicted risk scores in the TAVR population ( Figure 1 ). When applied in a population with TAVR, the C statistic for the standard STS valve mortality risk model and EuroSCORE model was only 0.60 and 0.53, respectively. 10 Only the TVT Registry and the FRANCE-2 models 12 are based solely on a population with TAVR. The models accounted for very similar covariates as a predictor of mortality after TAVR (age, NYHA class, chronic lung disease, acuity, chronic kidney disease, and non-femoral approach). However, the C statistic of 0.66 for the TVT Registry model derived showed only slight improvement over the previously reported models. 13 There is no doubt that important variables are not accounted for in risk stratification of patients undergoing TAVR. Frailty indices such as the 5-m gait speed and quality of life measures such as the Kansas City Cardiomyopathy Questionnaire are generally recognized as potentially important factors and are not yet included in any risk score.
14 However, the TVT Registry is currently collecting frailty and quality of life data to include in future 30-day and 1-year risk models. In this study, MAC was an independent risk factor for mortality irrespective of the STS score. One-year all-cause mortality and 12.3%, P = 0.03; and 11.6% vs. 4.7%, P = 0.02, respectively). Therefore, severe MAC should not be overlooked when evaluating patients with TAVR and may be considered in future risk stratification models as severe MAC is a marker of more advanced disease and atherosclerotic burden, and is responsible for the increased mortality seen in this subset of patients after TAVR.
New PPM implantation remains one of the Achilles heels of TAVR. Studies evaluating the outcomes of conduction abnormalities after TAVR have yielded inconsistent results, but some limited data suggest a potential effect on mortality and LV function. 15 Furthermore, PPM carries a risk of infective endocarditis. An increased rate of conduction abnormalities has been reported for some of the newer transcatheter heart valves and could potentially be a barrier towards wide adoption in younger and lower risk patients. As shown previously, right bundle branch block (RBBB), use of self-expanding valves, and LVOT calcifications were independent predictors for new PPM implantation in this study. In addition, severe MAC was found to be a strong predictor of new PPM implantation following TAVR (odds ratio 2.83). The higher incidence of conduction disease is most likely to be due to calcification in the vicinity of the atrioventricular node and the bundle of His, as well as diffuse degenerative conduction system disease that is frequently associated with MAC. In patients with severe MAC, no pre-dilation or pre-dilation with an undersized balloon, relatively high implant, use of transcatheter heart valves with a record of low PPM rates, and avoidance of post-dilation seem to be prudent to avoid interaction with the disease conduction system. Mitral regurgitation (MR) is not uncommon in TAVR patients and is a main driver of subsequent clinical outcomes. 16 However, the predictors of MR improvement are not well defined. In a recent study, calcification of the mitral apparatus by multidetector CT (MDCT) was the strongest parameter for predicting lack of MR improvement post-TAVR. 17 Although not statistically significant, subgroup analysis revealed a trend towards less improvement in patients with severe MAC (33.2% of patients with nonsevere MAC had one grade or more MR improvement vs. 22.0% of patients with severe MAC, P = 0.14). A probable mechanism for this association is the calcium infiltration at the base of the posterior leaflet which reduces leaflet mobility, increases traction on the chordae, and lifts the leaflets. Indeed, MAC can potentially impinge and restrict leaflet motion and is associated with lack of reduction in MR improvement after TAVR.
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Severe MAC was associated with an elevated gradient to>5 mmHg in around half of patients, and 6.9% had a gradient >10 mmHg consistent with severe mitral stenosis. This is an important consideration especially when MAC is associated with severe mitral stenosis as this could affect the decision-making and can identify a subset of patients that can benefit from mitral valve intervention after TAVR, or surgical approach to both valves although associated with high operative morbidity and mortality in the setting of severe MAC. 19 Moreover, transcatheter mitral valve replacement for severe MAC is associated with prosthesis anchoring issues, LVOT obstruction, and paravalvular leak, and is technically challenging. The presence of MAC in patients referred for TAVR should not go unnoticed, and careful quantification, proper risk assessment, and careful procedural planning should be undergone in order to maximize outcomes. 
